Klaria Pharma initiates clinical study with Naloxon Alginate Film
UPPSALA, 20 December, 2021. Klaria Pharma AB (Nasdaq Stockholm: KLAR) announces today that is has started a clinical trial with Naloxone Alginate Film and that the first group of subjects have received their first doses in the trial. The data from this clinical trial will be used to submit an application for approval with both the EMA in Europe and the FDA in the United States. With a more patient friendly formulation that is being specifically developed to meet the needs of patients and caregivers today, Naloxone Alginate Film has the potential to be superior to all Naloxone nasal sprays